Calcineurin inhibition and new-onset diabetes mellitus after transplantation

Transplantation

Volumn 95, Issue 5, 2013, Pages 647-652

  Chakkera, Harini A ^a   Mandarino, Lawrence J ^b  

^a MAYO CLINIC HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Glucose intolerance; Insulin resistance; Insulin secretion

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GLUCOSE; INSULIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

APOPTOSIS; DIABETES MELLITUS; DIABETOGENESIS; DRUG MECHANISM; GRAFT SURVIVAL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY TRANSPLANTATION; MORBIDITY; NEW ONSET DIABETES MELLITUS; NEW ONSET DIABETES MELLITUS AFTER TRANSPLANTATION; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKELETAL MUSCLE; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; ORGAN TRANSPLANTATION; PHYSIOLOGY;

ANIMALS; CALCINEURIN; DIABETES MELLITUS; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; ORGAN TRANSPLANTATION;

MLCS; MLOWN;

EID: 84877302285     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826e592e     Document Type: Review

References (75)

1. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440.
2. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
3. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007; 83: 1027.
4. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
5. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
6. Kahn SE. The relative contributions of insulin resistance and A-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3.
7. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and A-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68: 1456.
8. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and A-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663.
9. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787.
10. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
11. Yang SB, Lee HY, Young DM, et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med 2012; 90: 575.
12. Tsang CK, Qi H, Liu LF, et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov today 2007; 12: 112.
13. Ozbay LA, Smidt K, Mortensen DM, et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E A-cells. Br J Pharmacol 2011; 162: 136.
14. Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet A-cell survival. J Biol Chem 2010; 285: 40050.
15. Kutkuhn B, Hollenbeck M, Heering P, et al. Development of insulin resistance and elevated blood pressure during therapy with cyclo-sporine A. Blood Press 1997; 6: 13.
16. Ryder JW, Bassel-Duby R, Olson EN, et al. Skeletal muscle reprogramming by activation of calcineurin improves insulin action on metabolic pathways. J Biol Chem 2003; 278: 44298.
17. Wahlstrom HE, Akimoto R, Endres D, et al. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 1992; 53: 1190.
18. Klee CB, Draetta GF, Hubbard MJ. Calcineurin. Adv Enzymol Relat Areas Mol Biol 1988; 61: 149.
19. Ebihara K, Fukunaga K, Matsumoto K, et al. Cyclosporin A stimulation of glucose-induced insulin secretion in MIN6 cells. Endocrinology 1996; 137: 5255.
20. Redmon JB, Olson LK, Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 2786.
21. Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic A-cell. Transplantation 1995; 59: 1606.
22. Furstenau U, Schwaninger M, Blume R, et al. Characterization of a novel calcium response element in the glucagon gene. J Biol Chem 1999; 274: 5851.
23. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707.
24. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002; 190(suppl 1): S67.
25. Shaw JP, Utz PJ, Durand DB, et al. Identification of a putative regulator of early T cell activation genes. Science 1988; 241: 202.
26. Graef IA, Chen F, Crabtree GR. NFAT signaling in vertebrate development. Curr Opin Genet Dev 2001; 11: 505.
27. Hogan PG, Chen L, Nardone J, et al. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003; 17: 2205.
28. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005; 5: 472.
29. Griffith JP, Kim JL, Kim EE, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 1995; 82: 507.
30. Jin L, Harrison SC. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A 2002; 99: 13522.
31. Kissinger CR, Parge HE, Knighton DR, et al. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 1995; 378: 641.
32. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
33. Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A 1995; 92: 11205.
34. Screaton RA, Conkright MD, Katoh Y, et al. The CREB coactivator TORC2 functions as a calcium-and cAMP-sensitive coincidence detector. Cell 2004; 119: 61.
35. Jhala US, Canettieri G, Screaton RA, et al. cAMP promotes pancreatic A-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003; 17: 1575.
36. Conkright MD, Canettieri G, Screaton R, et al. TORCs: transducers of regulated CREB activity. Mol Cell 2003; 12: 413.
37. Iourgenko V, Zhang W, Mickanin C, et al. Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc Natl Acad Sci U S A 2003; 100: 12147.
38. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391: 900.
39. DeFronzo RA. Lilly lecture 1987. The triumvirate: A-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667.
40. DeFronzo RA, Jacot E, Jequier E, et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981; 30: 1000.
41. Firth RG, Bell PM, Marsh HM, et al. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. J Clin Invest 1986; 77: 1525.
42. Pette D, Staron RS. Myosin isoforms, muscle fiber types, and transitions. Microsc Res Tech 2000; 50: 500.
43. Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 1996; 76: 371.
44. Chin ER, Allen DG. The role of elevations in intracellular [Ca2+] in the development of low frequency fatigue in mouse single muscle fibres. J Physiol 1996; 491(pt 3): 813.
45. Hennig R, Lomo T. Firing patterns of motor units in normal rats. Nature 1985; 314: 164.
46. Westerblad H, Allen DG. Changes of myoplasmic calcium concentration during fatigue in single mouse muscle fibers. J Gen Physiol 1991; 98: 615.
47. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinaseY and MAP kinaseYmediated signaling in human muscle. J Clin Invest 2000; 105: 311.
48. Rizza RA, Mandarino LJ, Gerich JE. Mechanism and significance of insulin resistance in nonYinsulin-dependent diabetes mellitus. Diabetes 1981; 30: 990.
49. Delling U, Tureckova J, Lim HW, et al. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavyYchain expression. Mol Cell Biol 2000; 20: 6600.
50. Graef IA, Chen F, Chen L, et al. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 2001; 105: 863.
51. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 > drives the formation of slow-twitch muscle fibres. Nature 2002; 418: 797.
52. McKinsey TA, Zhang CL, Lu J, et al. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000; 408: 106.
53. Chin ER, Olson EN, Richardson JA, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998; 12: 2499.
54. Friday BB, Mitchell PO, Kegley KM, et al. Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD. Differentiation 2003; 71: 217.
55. Wu H, Naya FJ, McKinsey TA, et al. MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type. EMBO J 2000; 19: 1963.
56. Wu H, Rothermel B, Kanatous S, et al. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J 2001; 20: 6414.
57. Dodou E, Xu SM, Black BL. Mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo. Mech Dev 2003; 120: 1021.
58. Shi H, Scheffler JM, Pleitner JM, et al. Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling. FASEB J 2008; 22: 2990.
59. Potthoff MJ, Wu H, Arnold MA, et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofi-bers. J Clin Invest 2007; 117: 2459.
60. Leone TC, Lehman JJ, Finck BN, et al. PGC-1> deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005; 3: e101.
61. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1>Yresponsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet 2003; 34: 267.
62. De Filippis E, Alvarez G, Berria R, et al. Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise. Am J Physiol Endocrinol Metab 2008; 294: E607.
63. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mi-tochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115.
64. Calabria E, Ciciliot S, Moretti I, et al. NFAT isoforms control activity-dependent muscle fiber type specification. Proc Natl Acad Sci U S A 2009; 106: 13335.
65. Jiang LQ, Garcia-Roves PM, de Castro Barbosa T, et al. Constitutively active calcineurin in skeletal muscle increases endurance performance and mitochondrial respiratory capacity. Am J Physiol Endocrinol Metab 2010; 298: E8.
66. Cowling BS, McGrath MJ, Nguyen MA, et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol 2008; 183: 1033.
67. Musaro A, McCullagh KJ, Naya FJ, et al. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-AT c 1. Nature 1999; 400: 581.
68. McCullagh KJ, Calabria E, Pallafacchina G, et al. NFAT is a nerve activity sensor in skeletal muscle and controls activity-dependent myo-sin switching. Proc Natl Acad Sci U S A 2004; 101: 10590.
69. Rana ZA, Gundersen K, Buonanno A. Activity-dependent repression of muscle genes by NFAT. Proc Natl Acad Sci U S A 2008; 105: 5921.
70. Simoneau JA, Colberg SR, Thaete FL, et al. Skeletal muscle glyco-lytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J 1995; 9: 273.
71. Lefort N, Glancy B, Bowen B, et al. Increased reactive oxygen species production and lower abundance of complex I subunits and carnitine palmitoyltransferase 1B protein despite normal mitochondrial respiration in insulin-resistant human skeletal muscle. Diabetes 2010; 59: 2444.
72. Hwang H, Bowen BP, Lefort N, et al. Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes. Diabetes 2010; 59: 33.
73. Painter P, Ward K, Nelson RD. Self-reported physical activity in patients with end stage renal disease. Nephrol Nurs J 2011; 38: 139.
74. Wlodarek D, Glabska D, Rojek-Trebicka J. Physical activity of predia-lysis patients with chronic kidney disease measured using SenseWear Armban. J Sports Med Phys Fitness 2011; 51: 639.
75. van den Ham EC, Kooman JP, Schols AM, et al. The functional, metabolic, and anabolic responses to exercise training in renal transplant and hemodialysis patients. Transplantation 2007; 83: 1059.